News and Presentations


Vaxxilon Shares Transferred to Idorsia as part of the J&J Actelion Acquisition
June 16, 2017

Actelion Ltd was the principal investor and majority shareholder of Vaxxilon AG since its inception in June 2015. In association with the Actelion acquisition by Janssen Holding GmbH, an indirect subsidiary of Johnson & Johnson, Actelion carried out a demerger of Actelion’s drug discovery and early clinical pipeline assets into Idorsia, a newly formed company, headquartered in Allschwil, Switzerland. The Vaxxilon shareholding was among these assets.

Peter Seeberger Presents at the Perlen der Forschung für die Anwendung
January 13, 2017

Peter Seeberger had the opportunity to present the science, technology, and global health implications of synthetic carbohydrate vaccines at the scientific forum “Pearls of Research and Their Applications” hosted by Chancellor Angela Merkel.


The Royal Society of Chemistry
January 11, 2017

Vaxxilon aims to simplify vaccine development by replacing biological components with well-defined synthetic molecules.


Vaxxilon – Falling Walls Science Start-up of the Year 2016
November 8, 2016

Vaxxilon selected as Science Startup of the year 2016 at Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models.

Vaxxilon builds management team
August 26, 2016

Vaxxilon AG today announced that Arne von Bonin, PhD has been appointed to the role of Chief Scientific Officer (CSO). Dr. von Bonin is responsible for preclinical and early phase development for Vaxxilon’s multiple projects including the design, implementation and execution of proof of concept and toxicology studies, Phase 1/2 trials and associated regulatory filings.

1 2
Basel Area
Vaxxilon AG
Christoph Merian-Ring 11,
4153 Reinach, Switzerland
Berlin Area (Adlershof)
Vaxxilon Deutschland GmbH
Magnusstraße 11,
12489 Berlin, Germany

Copyright 2019 © Vaxxilon AG